What's New

CE Education
2016 EHA Annual Meeting Highlights in HL
Peter Borchmann, MD; Paul Bröckelmann, MD; Astrid Pavlovsky, MD; and Anas Younes, MD
CE Education
First-line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early- versus Advanced-Stage Disease
Andrew M. Evens, DO, MSc, FACP
CE Education
Aiming for a Higher Cure Rate: Strategies for Salvage Treatment at Relapse in HL
Robert W. Chen, MD
Case Discussion
Case Study of a Newly Diagnosed HL Patient: The Role of CD30 from Diagnosis to Treatment
Andreas Engert, MD
FAQ Library
What treatment approaches may increase chances for a higher cure rate in patients with R/R HL?
Robert W. Chen, MD
FAQ Library
When is it appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of HL?
Which factors are more important when developing treatment plans for the newly diagnosed HL patient?
Andrew Evens, DO, MSc, FACP
FAQ Library
Is there a changing paradigm in the management of patients with relapsed or refractory HL?
Robert W. Chen, MD
FAQ Library
What alternatives may be used to accurately stage Hodgkin lymphoma if PET-CT is not available?
Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?
What strategies can be utilized to accurately diagnose Hodgkin lymphoma in areas that lack adequate pathology?
Bruce D. Cheson, MD
The Managing Hodgkin Lymphoma Expert Interview Series
In this series, Dr. George Davatelis interviews various clinical experts from around the globe regarding clinical challenges they experience in managing patients with HL.

Managing HL would like to recognize and thank Takeda Oncology for its educational support of ManagingHodgkinLymphoma.com

©2016 MediCom Worldwide, Inc. All rights reserved